CINECA IRIS Institutional Research Information System

FOGLI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.256
EU - Europa 4.234
AS - Asia 3.021
SA - Sud America 498
AF - Africa 196
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 3
Totale 16.241
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.986
IT - Italia 1.371
CN - Cina 974
SG - Singapore 834
DE - Germania 712
SE - Svezia 633
HK - Hong Kong 496
BR - Brasile 438
GB - Regno Unito 295
BG - Bulgaria 285
CA - Canada 201
TR - Turchia 187
RU - Federazione Russa 156
FI - Finlandia 141
AT - Austria 131
IN - India 130
VN - Vietnam 114
FR - Francia 107
CI - Costa d'Avorio 81
UA - Ucraina 75
PL - Polonia 64
GR - Grecia 47
JP - Giappone 45
NL - Olanda 39
BE - Belgio 38
CH - Svizzera 38
MX - Messico 38
SN - Senegal 37
BD - Bangladesh 36
AU - Australia 31
ES - Italia 26
IL - Israele 23
IR - Iran 22
PK - Pakistan 21
KR - Corea 19
NG - Nigeria 18
SA - Arabia Saudita 18
AR - Argentina 17
RO - Romania 17
MA - Marocco 15
IQ - Iraq 14
ID - Indonesia 13
ZA - Sudafrica 13
CO - Colombia 12
PT - Portogallo 11
RS - Serbia 11
AE - Emirati Arabi Uniti 8
EG - Egitto 8
TW - Taiwan 8
EC - Ecuador 7
KE - Kenya 7
NP - Nepal 7
UY - Uruguay 7
UZ - Uzbekistan 7
VE - Venezuela 7
HU - Ungheria 6
JM - Giamaica 6
PH - Filippine 6
CZ - Repubblica Ceca 5
JO - Giordania 5
MY - Malesia 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
CL - Cile 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
LB - Libano 4
TN - Tunisia 4
AL - Albania 3
BJ - Benin 3
BO - Bolivia 3
CY - Cipro 3
DM - Dominica 3
IE - Irlanda 3
KG - Kirghizistan 3
LT - Lituania 3
NO - Norvegia 3
PA - Panama 3
A1 - Anonimo 2
AM - Armenia 2
BB - Barbados 2
BY - Bielorussia 2
CR - Costa Rica 2
DK - Danimarca 2
KZ - Kazakistan 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
PY - Paraguay 2
SI - Slovenia 2
SV - El Salvador 2
TH - Thailandia 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BW - Botswana 1
DZ - Algeria 1
EU - Europa 1
Totale 16.224
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.048
Ashburn 716
Fairfield 702
Santa Clara 618
Ann Arbor 604
Chandler 604
Houston 553
Hong Kong 485
Singapore 352
Serra 307
Shanghai 294
Sofia 284
Seattle 275
Wilmington 264
Cambridge 213
Milan 202
New York 194
Beijing 186
Ottawa 157
Boardman 148
Princeton 144
Lawrence 119
Pisa 119
Vienna 118
Izmir 105
Medford 105
Jacksonville 94
Los Angeles 91
Nanjing 85
Florence 83
Munich 83
Abidjan 81
London 72
Frankfurt am Main 69
Dearborn 67
Rome 65
Des Moines 61
Dong Ket 54
Redwood City 54
Warsaw 51
Istanbul 46
Hefei 45
Ogden 45
Lancaster 39
Dakar 37
São Paulo 37
Marseille 35
Bern 33
Nanchang 33
Turku 33
San Diego 32
The Dalles 29
Tokyo 29
Brussels 27
Columbus 27
Council Bluffs 25
Jüchen 25
Falls Church 24
Bremen 22
Kunming 22
Fuzhou 21
Pune 21
Nürnberg 20
Toronto 20
Changsha 19
San Francisco 19
Tianjin 19
Belo Horizonte 18
Lagos 18
Phoenix 17
Cascina 15
Norwalk 15
Dallas 14
Helsinki 14
Lucca 14
Naples 14
Pistoia 14
Hebei 13
Livorno 13
Quanzhou 13
Chicago 12
Düsseldorf 12
Guangzhou 12
Seoul 12
Shenyang 12
Tel Aviv 12
Wuhan 12
Auburn Hills 11
Boulder 11
Dhaka 11
Mumbai 11
Rio de Janeiro 11
Washington 11
Brasília 10
Chaumont-gistoux 10
Delhi 10
Jiaxing 10
Nuremberg 10
Turin 10
Bologna 9
Totale 11.121
Salva come PNG Salva come JPEG
Nome #
The molecular bases of cannabinoid action in cancer 317
Cytotoxic Activity of Oleocanthal Isolated from Virgin Olive Oil on Human Melanoma Cells 299
AM251 induces apoptosis and G2/M cell cycle arrest in A375 human melanoma cells 264
Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer 252
Anticancer activity of euplotin C, isolated from the marine ciliate euplotes crassus, against human melanoma cells 238
Circulating MicroRNAs in Cutaneous Melanoma Diagnosis and Prognosis 233
Sucrosomial iron and traditional iron dosage forms are compared for absorption by Caco2 cells. 226
Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism 210
A flexible SNP genotyping system to study allelic determinants of brain function. 202
Cholinesterase-like organocatalysis by imidazole and imidazole-bearing molecules 199
Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia 199
Survivin-directed molecular beacon as potential theranostic agent in melanoma cells 189
Oleocanthal and oleacein contribute to the in vitro therapeutic potential of extra virgin oil-derived extracts in non-melanoma skin cancer 189
New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity 187
Analysis of the Antitumor Activity of Clotrimazole on A375 Human Melanoma Cells 183
Chronic administration of suramin induces neurotoxicity in rats 179
Protective effect of high-dose montelukast on salbutamol-induced homologous desensitisation in airway smooth muscle. 177
Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma 177
Anticancer activity of anandamide in human cutaneous melanoma cells 175
Rosiglitazone reverses salbutamol-induced ß(2) -adrenoceptor tolerance in airway smooth muscle. 170
Detection and silencing of survivin mRNA by bi-color imaging based on PMMA nanoparticles/molecular beacon in human cancer cells 169
Anti-proliferative activity of oleocanthal in human malignant cutaneous melanoma cells 167
Survivin mRNA detection and silencing by a Molecular Beacon Oligodeoxynucleotide in living cutaneous melanoma cells 163
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. 163
Selection of a human butyrylcholinesterase-like antibody single-chain variable fragment resistant to AChE inhibitors from a phage library expressed in E. coli. 162
Survivin directed molecular beacon as potential “theranostic agent” in melanoma cells 161
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 158
Lung tissue penetration and plasma pharmacokinetics of azithromycin after multiple oral doses of 500 and 1000 mg in adults 156
Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. 155
Tumor-promoting effects of cannabinoid receptor type 1 in human melanoma cells. 154
Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells 154
Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives 153
Cytotoxic effects of Echinacea root hexanic extracts on human cancer cell lines 153
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 153
Antiproliferative effects of Echinacea root hexanic extracts on Mia Paca-2 cells 151
Theranostic properties of a survivin-directed molecular beacon in human melanoma cells 150
Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation. 149
Pharmacogenetic determinants of anti-cancer drug activity and toxicity 149
Matrix metalloproteinase inhibitors prevent the release and proteolytic activity of monocyte/macrophage-derived microparticles 144
Cannabinoid derivatives induce cell death in MIA Paca-2 cell line via a receptor-indipendent mechanism 143
Ceramide analogues in apoptosis: a new strategy for anticancer drug development 143
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer 143
Role of miR-34a as biomarker and therapeutic agent in cutaneous melanoma 143
A flexible SNP genotyping system to study allelic determinants of brain function 142
Clinical pharmacology of intravitreal anti-VEGF drugs 142
Montelukast reverses albuterol-induced b2-adrenoceptor tolerance in airway smooth muscle 141
Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer 141
Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma 139
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 138
Design, synthesis and pro-apoptotic antitumour properties of indole-based 3,5-disubstituted oxadiazoles 137
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema 137
Montelukast prevents microparticle-induced inflammatory and functional alterations in human bronchial smooth muscle cells. 137
Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo 136
Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues 135
Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells 134
Identification of five circulating microRNAs with high diagnostic values in cutaneous melanoma 134
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy 134
Potential relationship between the expression of Cx26/Cx43 and the BRAF mutation status in human melanoma cells 132
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 131
Synthesis, characterization and evaluation of thiolated quaternary ammonium-chitosan conjugates for enhanced intestinal drug permeation 130
Synthesis and evaluation of indole-containing 3,5-diarylisoxazoles as potential pro-apoptotic antitumour agents. 130
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study 130
Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer 130
Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management 130
Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity 129
Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins 125
In vitro investigation of sulindac derivatives as potential anticancer agents 122
Sucrosomial® iron absorption studied by in vitro and ex-vivo models 122
Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells 120
Farmacogenetica nelle neoplasie gastriche 118
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 116
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs 115
In vivo adenosine A(2B) receptor desensitization in guinea-pig airway smooth muscle: Implications for asthma 115
New chitosan derivatives for the preparation of rokitamycin loaded microspheres designed for ocular or nasal administration 114
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide 114
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients 113
Influence of polysaccharides on expression of membrane-associated muc1 in cultivated epithelial cells 112
Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens 112
Synthesis, characterization and evaluation of thiolated quaternary ammonium-chitosan conjugates for enhanced intestinal drug permeation 110
null 110
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study 109
The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage 108
Attività antiproliferativa dell’oleocantale in cellule umane di melanoma cutaneo maligno. 107
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 102
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors 99
Evaluation of circulating microRNAs as diagnostic circulating biomarkers in cutaneous melanoma 98
Cross-Linked Hyaluronic Acid as Tear Film Substitute 97
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 97
ErbB in NSCLC as a molecular target: Current evidences and future directions 97
Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting 97
null 96
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer 96
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 95
Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer 94
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs 94
Control of cell growth by ceramide analogues: a new strategy for anticancer drug development 92
Effetto dell'introduzione di porzioni lipofile o idrofile sull'attività antiproliferativa di analoghi semirigidi delle ceramidi intracellulari 87
Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview 87
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors 86
null 85
Totale 14.431
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.901
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.901
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.088 79 71 57 78 103 67 67 94 135 116 78 143
2021/20221.479 43 77 65 90 233 212 60 70 63 49 86 431
2022/20232.062 257 292 162 169 194 278 37 152 371 10 126 14
2023/20241.411 142 163 158 83 176 252 71 52 29 51 107 127
2024/20254.463 49 173 47 245 506 530 294 200 479 525 456 959
2025/2026104 104 0 0 0 0 0 0 0 0 0 0 0
Totale 16.635